Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Andrew D.W. HillAndrew Hill Investment Advisors, Inc. | BiotechnologyBiotechnology | Andrew Hill Investment Advisors - VRTX Vertex Pharmaceuticals has caught the eye of investors as well. Vertex is developing... | NEUTRAL | View Pitch → | |
| Feb 25, 2026 | Fund Letter | Dr. Hendrik LeberACATIS Investment | BiotechnologyBiotechnology | ACATIS Investment 2024 Q4 (VRTX) Vertex Pharmaceuticals has released disappointing data on its new pain relief medication, which is in clinical trials. It is supposed... | BULL | View Pitch → | |
| Jan 20, 2026 | Fund Letter | Cassandra A. HardmanHardman Johnston Global Equity | BiotechnologyBiotechnology | Hardman Johnston Global Equity 2025 Q4 (VRTX) Quarterly Liquidations: Vertex Pharmaceuticals Inc. BSD Analysis: Vertex is a rare biotech that prints cash like a consumer staples company. Cystic fibrosis dominance... | BULL | View Pitch → | |
| Jan 8, 2026 | Fund Letter | Cassandra A. HardmanHardman Johnston Global Equity | BiotechnologyBiotechnology | Hardman Johnston Global Equity 2025 Q2 (VRTX) Vertex shares struggled after the company reported a Q1 top-line miss, driven by the one-time impact of a counterfeit version of their cystic fibrosis drug Trikafta in Russia. We do not... | BULL | View Pitch → | |
| Jan 8, 2026 | Fund Letter | Aziz HamzaogullariLoomis Sayles Global Growth Fund | BiotechnologyBiotechnology | Loomis Sayles Global Growth Fund 2025 Q2 (VRTX) Vertex Pharmaceuticals, founded in 1989, is a global biopharmaceutical company with deep expertise in protein and genetic science and a focus on specialty markets. The company is... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.